UPB
What one share of Upstream Bio holds
Pharmaceutical Preparations
We are a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders.
Upstream Bio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.06 |
|---|---|
| Profit | −$2.89 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$2.52 |
| Cash and investments | $1.45 |
| Book value | $4.95 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | $0.81 | −$12.95 | $0.05 | −$12.89 | — | −$41.15 |
| 2024 | $0.17 | −$5.58 | $0.04 | −$4.36 | — | — |
| 2025 | $0.05 | −$2.66 | $0.00 | −$2.48 | — | $6.26 |